Jim Simons Fulcrum Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$5.98 - $9.31 $79,276 - $123,422	13,257 New	13,257 $82,000
Q3 2023 Nov 14, 2023	SELL	$3.25 - $6.08 $949,247 - $1.78 Million	-292,076 Reduced 84.71%	52,734 $234,000
Q2 2023 Aug 11, 2023	SELL	$2.26 - $3.8 $102,355 - $172,102	-45,290 Reduced 11.61%	344,810 $1.14 Million
Q1 2023 May 12, 2023	BUY	$2.83 - $13.99 $1.1 Million - $5.46 Million	390,100 New	390,100 $1.11 Million
Q2 2022 Aug 12, 2022	BUY	$4.2 - $24.0 $285,600 - $1.63 Million	68,000 New	68,000 $333,000
Q4 2021 Feb 11, 2022	SELL	$14.0 - $28.44 $1.87 Million - $3.81 Million	-133,900 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$7.28 - $30.97 $974,792 - $4.15 Million	133,900 New	133,900 $3.78 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $156M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.